1. Home
  2. VNDA vs MXCT Comparison

VNDA vs MXCT Comparison

Compare VNDA & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VNDA
  • MXCT
  • Stock Information
  • Founded
  • VNDA 2002
  • MXCT 1999
  • Country
  • VNDA United States
  • MXCT United States
  • Employees
  • VNDA N/A
  • MXCT N/A
  • Industry
  • VNDA Biotechnology: Pharmaceutical Preparations
  • MXCT Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • VNDA Health Care
  • MXCT Health Care
  • Exchange
  • VNDA Nasdaq
  • MXCT Nasdaq
  • Market Cap
  • VNDA 261.7M
  • MXCT 239.2M
  • IPO Year
  • VNDA 2006
  • MXCT 2021
  • Fundamental
  • Price
  • VNDA $4.78
  • MXCT $2.24
  • Analyst Decision
  • VNDA Strong Buy
  • MXCT Strong Buy
  • Analyst Count
  • VNDA 3
  • MXCT 1
  • Target Price
  • VNDA $15.33
  • MXCT $9.00
  • AVG Volume (30 Days)
  • VNDA 408.4K
  • MXCT 717.0K
  • Earning Date
  • VNDA 07-30-2025
  • MXCT 08-06-2025
  • Dividend Yield
  • VNDA N/A
  • MXCT N/A
  • EPS Growth
  • VNDA N/A
  • MXCT N/A
  • EPS
  • VNDA N/A
  • MXCT N/A
  • Revenue
  • VNDA $201,351,000.00
  • MXCT $37,675,000.00
  • Revenue This Year
  • VNDA $16.86
  • MXCT $8.82
  • Revenue Next Year
  • VNDA $39.78
  • MXCT $21.12
  • P/E Ratio
  • VNDA N/A
  • MXCT N/A
  • Revenue Growth
  • VNDA 13.37
  • MXCT N/A
  • 52 Week Low
  • VNDA $3.81
  • MXCT $2.00
  • 52 Week High
  • VNDA $6.37
  • MXCT $5.20
  • Technical
  • Relative Strength Index (RSI)
  • VNDA 53.88
  • MXCT 48.76
  • Support Level
  • VNDA $4.85
  • MXCT $2.16
  • Resistance Level
  • VNDA $5.12
  • MXCT $2.29
  • Average True Range (ATR)
  • VNDA 0.18
  • MXCT 0.12
  • MACD
  • VNDA 0.01
  • MXCT 0.01
  • Stochastic Oscillator
  • VNDA 54.05
  • MXCT 71.20

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

About MXCT MaxCyte Inc.

MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The Company has one reportable segment, cell engineering technology. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.

Share on Social Networks: